Organization | CHA Vaccine Institute Co., Ltd.

CHA Vaccine Institute Co., Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Seongnam Korea, Republic of (2000)

Status: Defunct (2019)

Organization Overview

First Clinical Trial

2012

NCT02692170

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

CHA Vaccine Institute Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

cvi-hbv-001 (1 trial)

cvi-hbv-002 (3 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

Drugs in Phase 1 Trials (2)

cvi-vzv-001 (1 trial)

varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 5